Treatment of cuff tendinopathy with platelet lysis

Phase 3

• Conditions: Cuff tendinopathy.; Unspecified rotator cuff tear or rupture of right shoulder, not specified as traumatic; M75.101

• Registration Number: IRCT20160422027520N17
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Men and women between the ages of 18 and 75 with cuff tendinopathy
The availability of individual during the study period

Exclusion Criteria

People under the age of 18 and over 75 years
Pregnant women or women who are breastfeeding
People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome
Those linked to acetaminophen or Vicodin or a history of drug misuse
History of cortisone injections in the last 6 weeks
The use of non-steroidal anti-inflammatory drugs 1 week ago
Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ
The use of inhibitors of platelet aggregation and anti-coagulation such as heparin
History of cuff surgery in the last 3 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determining cuff pain by VAS in all phases of clinical trial. Timepoint: 1 and 3 months after the first injection. Method of measurement: Questionnaire (VAS).;Determination of cuff function by Shoulder Pain and Disability Index (SPADI) in all phases of clinical trial. Timepoint: 1 and 3 months after the first injection. Method of measurement: Questionnaire (SPADI).;Determine the range of cuff motion by manual joiniometry in all phases of clinical trial. Timepoint: 1 and 3 months after the first injection. Method of measurement: Range of motion (Degree).